ID   MET_HUMAN               Reviewed;        1390 AA.
AC   P08581; A1L467; B5A932; E7EQ94; O60366; Q12875; Q9UDX7; Q9UPL8;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 4.
DT   12-OCT-2022, entry version 267.
DE   RecName: Full=Hepatocyte growth factor receptor;
DE            Short=HGF receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=HGF/SF receptor;
DE   AltName: Full=Proto-oncogene c-Met;
DE   AltName: Full=Scatter factor receptor;
DE            Short=SF receptor;
DE   AltName: Full=Tyrosine-protein kinase Met;
DE   Flags: Precursor;
GN   Name=MET;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2819873; DOI=10.1073/pnas.84.18.6379;
RA   Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G.;
RT   "Sequence of MET protooncogene cDNA has features characteristic of the
RT   tyrosine kinase family of growth-factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6379-6383(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Giordano S.;
RL   Submitted (NOV-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1010-1390.
RX   PubMed=3325883;
RA   Chan A.M.-L., King H.W.S., Tempest P.R., Deakin E.A., Cooper C.S.,
RA   Brookes P.;
RT   "Primary structure of the met protein tyrosine kinase domain.";
RL   Oncogene 1:229-233(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1206-1264.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1267-1390.
RX   PubMed=4069211; DOI=10.1038/318385a0;
RA   Dean M., Park M., le Beau M.M., Robins T.S., Diaz M.O., Rowley J.D.,
RA   Blair D.G., Vande Woude G.F.;
RT   "The human met oncogene is related to the tyrosine kinase oncogenes.";
RL   Nature 318:385-388(1985).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=1917129; DOI=10.1002/ijc.2910490302;
RA   Prat M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G.,
RA   Comoglio P.M.;
RT   "The receptor encoded by the human c-MET oncogene is expressed in
RT   hepatocytes, epithelial cells and solid tumors.";
RL   Int. J. Cancer 49:323-328(1991).
RN   [12]
RP   INTERACTION WITH PIK3R1.
RX   PubMed=1718989; DOI=10.1016/s0021-9258(18)54536-1;
RA   Graziani A., Gramaglia D., Cantley L.C., Comoglio P.M.;
RT   "The tyrosine-phosphorylated hepatocyte growth factor/scatter factor
RT   receptor associates with phosphatidylinositol 3-kinase.";
RL   J. Biol. Chem. 266:22087-22090(1991).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=1719465;
RA   Di Renzo M.F., Narsimhan R.P., Olivero M., Bretti S., Giordano S.,
RA   Medico E., Gaglia P., Zara P., Comoglio P.M.;
RT   "Expression of the Met/HGF receptor in normal and neoplastic human
RT   tissues.";
RL   Oncogene 6:1997-2003(1991).
RN   [14]
RP   FUNCTION.
RX   PubMed=1846706; DOI=10.1126/science.1846706;
RA   Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M.-L., Kmiecik T.E.,
RA   Vande Woude G.F., Aaronson S.A.;
RT   "Identification of the hepatocyte growth factor receptor as the c-met
RT   proto-oncogene product.";
RL   Science 251:802-804(1991).
RN   [15]
RP   PHOSPHORYLATION AT TYR-1235, AND ATP-BINDING SITE LYS-1110.
RX   PubMed=1655790; DOI=10.1016/s0021-9258(18)55031-6;
RA   Ferracini R., Longati P., Naldini L., Vigna E., Comoglio P.M.;
RT   "Identification of the major autophosphorylation site of the Met/hepatocyte
RT   growth factor receptor tyrosine kinase.";
RL   J. Biol. Chem. 266:19558-19564(1991).
RN   [16]
RP   PHOSPHORYLATION AT TYR-1349 AND TYR-1356, AND INTERACTION WITH SRC; PLCG1
RP   AND GRB2.
RX   PubMed=7513258; DOI=10.1016/0092-8674(94)90318-2;
RA   Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S.,
RA   Graziani A., Panayotou G., Comoglio P.M.;
RT   "A multifunctional docking site mediates signaling and transformation by
RT   the hepatocyte growth factor/scatter factor receptor family.";
RL   Cell 77:261-271(1994).
RN   [17]
RP   FUNCTION IN WOUND HEALING.
RX   PubMed=8182137; DOI=10.1172/jci117200;
RA   Nusrat A., Parkos C.A., Bacarra A.E., Godowski P.J., Delp-Archer C.,
RA   Rosen E.M., Madara J.L.;
RT   "Hepatocyte growth factor/scatter factor effects on epithelia. Regulation
RT   of intercellular junctions in transformed and nontransformed cell lines,
RT   basolateral polarization of c-met receptor in transformed and natural
RT   intestinal epithelia, and induction of rapid wound repair in a transformed
RT   model epithelium.";
RL   J. Clin. Invest. 93:2056-2065(1994).
RN   [18]
RP   INTERACTION WITH STAT3.
RX   PubMed=9440692; DOI=10.1038/34657;
RA   Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P.,
RA   Battistini C., Comoglio P.M.;
RT   "Induction of epithelial tubules by growth factor HGF depends on the STAT
RT   pathway.";
RL   Nature 391:285-288(1998).
RN   [19]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568; DOI=10.1128/mcb.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [20]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH L.MONOCYTOGENES INLB
RP   (MICROBIAL INFECTION), AND PHOSPHORYLATION (MICROBIAL INFECTION).
RX   PubMed=11081636; DOI=10.1016/s0092-8674(00)00141-0;
RA   Shen Y., Naujokas M., Park M., Ireton K.;
RT   "InIB-dependent internalization of Listeria is mediated by the Met receptor
RT   tyrosine kinase.";
RL   Cell 103:501-510(2000).
RN   [21]
RP   INTERACTION WITH RANBP9.
RX   PubMed=12147692; DOI=10.1074/jbc.m205111200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM.";
RL   J. Biol. Chem. 277:36216-36222(2002).
RN   [22]
RP   UBIQUITINATION, MUTAGENESIS OF TYR-1234; TYR-1235; TYR-1313; TYR-1349;
RP   TYR-1356 AND TYR-1365, AND CHARACTERIZATION OF VARIANT SER-1003.
RX   PubMed=12244174; DOI=10.4049/jimmunol.169.7.3793;
RA   Taher T.E., Tjin E.P., Beuling E.A., Borst J., Spaargaren M., Pals S.T.;
RT   "c-Cbl is involved in Met signaling in B cells and mediates hepatocyte
RT   growth factor-induced receptor ubiquitination.";
RL   J. Immunol. 169:3793-3800(2002).
RN   [23]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=12198496; DOI=10.1038/ncb843;
RA   Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D.,
RA   Tamagnone L., Comoglio P.M.;
RT   "The semaphorin 4D receptor controls invasive growth by coupling with
RT   Met.";
RL   Nat. Cell Biol. 4:720-724(2002).
RN   [24]
RP   PHOSPHORYLATION AT TYR-1230; TYR-1234; TYR-1235; TYR-1349 AND TYR-1365, AND
RP   DEPHOSPHORYLATION AT TYR-1349 AND TYR-1365 BY PTPRJ.
RX   PubMed=12475979; DOI=10.1074/jbc.m210656200;
RA   Palka H.L., Park M., Tonks N.K.;
RT   "Hepatocyte growth factor receptor tyrosine kinase met is a substrate of
RT   the receptor protein-tyrosine phosphatase DEP-1.";
RL   J. Biol. Chem. 278:5728-5735(2003).
RN   [25]
RP   INTERACTION WITH RANBP9 AND RANBP10.
RX   PubMed=14684163; DOI=10.1016/j.bbrc.2003.11.124;
RA   Wang D., Li Z., Schoen S.R., Messing E.M., Wu G.;
RT   "A novel MET-interacting protein shares high sequence similarity with
RT   RanBPM, but fails to stimulate MET-induced Ras/Erk signaling.";
RL   Biochem. Biophys. Res. Commun. 313:320-326(2004).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH MUC20.
RX   PubMed=15314156; DOI=10.1128/mcb.24.17.7456-7468.2004;
RA   Higuchi T., Orita T., Katsuya K., Yamasaki Y., Akiyama K., Li H.,
RA   Yamamoto T., Saito Y., Nakamura M.;
RT   "MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by
RT   binding to a multifunctional docking site of met.";
RL   Mol. Cell. Biol. 24:7456-7468(2004).
RN   [27]
RP   PHOSPHORYLATION AT TYR-1356, AND INTERACTION WITH INPPL1.
RX   PubMed=15735664; DOI=10.1038/sj.onc.1208558;
RA   Koch A., Mancini A., El Bounkari O., Tamura T.;
RT   "The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met
RT   directly via tyrosine residue 1356 and involves hepatocyte growth factor
RT   (HGF)-induced lamellipodium formation, cell scattering and cell
RT   spreading.";
RL   Oncogene 24:3436-3447(2005).
RN   [28]
RP   REVIEW ON FUNCTION IN ANGIOGENESIS.
RX   PubMed=16862193; DOI=10.1038/nrc1912;
RA   Boccaccio C., Comoglio P.M.;
RT   "Invasive growth: a MET-driven genetic programme for cancer and stem
RT   cells.";
RL   Nat. Rev. Cancer 6:637-645(2006).
RN   [29]
RP   PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1 AND PTPN2, INTERACTION WITH
RP   PTPN1 AND PTPN2, AND MUTAGENESIS OF TYR-1234 AND TYR-1235.
RX   PubMed=18819921; DOI=10.1074/jbc.m805916200;
RA   Sangwan V., Paliouras G.N., Abella J.V., Dube N., Monast A., Tremblay M.L.,
RA   Park M.;
RT   "Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine
RT   phosphatase 1B and T-cell phosphatase.";
RL   J. Biol. Chem. 283:34374-34383(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-977 AND TYR-1003, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-990; SER-997 AND SER-1000,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [32]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-106.
RC   TISSUE=Hepatoma;
RX   PubMed=19196183; DOI=10.1021/pr800826u;
RA   Cao J., Shen C., Wang H., Shen H., Chen Y., Nie A., Yan G., Lu H., Liu Y.,
RA   Yang P.;
RT   "Identification of N-glycosylation sites on secreted proteins of human
RT   hepatocellular carcinoma cells with a complementary proteomics approach.";
RL   J. Proteome Res. 8:662-672(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1003 AND THR-1289, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=20655987; DOI=10.1016/j.bbcan.2010.07.006;
RA   Mahtouk K., Tjin E.P., Spaargaren M., Pals S.T.;
RT   "The HGF/MET pathway as target for the treatment of multiple myeloma and B-
RT   cell lymphomas.";
RL   Biochim. Biophys. Acta 1806:208-219(2010).
RN   [35]
RP   FUNCTION (MICROBIAL INFECTION), AND SUBUNIT (MICROBIAL INFECTION).
RX   PubMed=19900460; DOI=10.1016/j.jmb.2009.10.074;
RA   Ferraris D.M., Gherardi E., Di Y., Heinz D.W., Niemann H.H.;
RT   "Ligand-mediated dimerization of the Met receptor tyrosine kinase by the
RT   bacterial invasion protein InlB.";
RL   J. Mol. Biol. 395:522-532(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   INTERACTION WITH GAB1.
RX   PubMed=21784853; DOI=10.1074/jbc.m111.239384;
RA   Chaudhuri A., Xie M.H., Yang B., Mahapatra K., Liu J., Marsters S.,
RA   Bodepudi S., Ashkenazi A.;
RT   "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal
RT   transduction by the related receptor tyrosine kinases RON and MET.";
RL   J. Biol. Chem. 286:32762-32774(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-990, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-966, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   INVOLVEMENT IN OSFD, VARIANT OSFD 964-LEU--ASP-1010 DEL, TISSUE
RP   SPECIFICITY, AND UBIQUITINATION.
RX   PubMed=26637977; DOI=10.1016/j.ajhg.2015.11.001;
RA   Gray M.J., Kannu P., Sharma S., Neyt C., Zhang D., Paria N., Daniel P.B.,
RA   Whetstone H., Sprenger H.G., Hammerschmidt P., Weng A., Dupuis L.,
RA   Jobling R., Mendoza-Londono R., Dray M., Su P., Wilson M.J., Kapur R.P.,
RA   McCarthy E.F., Alman B.A., Howard A., Somers G.R., Marshall C.R.,
RA   Manners S., Flanagan A.M., Rathjen K.E., Karol L.A., Crawford H.,
RA   Markie D.M., Rios J.J., Wise C.A., Robertson S.P.;
RT   "Mutations preventing regulated exon skipping in MET cause osteofibrous
RT   dysplasia.";
RL   Am. J. Hum. Genet. 97:837-847(2015).
RN   [41]
RP   INVOLVEMENT IN DFNB97, AND VARIANT DFNB97 VAL-841.
RX   PubMed=25941349; DOI=10.1136/jmedgenet-2015-103023;
RA   Mujtaba G., Schultz J.M., Imtiaz A., Morell R.J., Friedman T.B., Naz S.;
RT   "A mutation of MET, encoding hepatocyte growth factor receptor, is
RT   associated with human DFNB97 hearing loss.";
RL   J. Med. Genet. 52:548-552(2015).
RN   [42]
RP   INTERACTION WITH HSP90AA1 AND HSP90AB1.
RX   PubMed=26517842; DOI=10.1371/journal.pone.0141786;
RA   Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C.,
RA   Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K.,
RA   Trepel J.B., Neckers L.;
RT   "Client proteins and small molecule inhibitors display distinct binding
RT   preferences for constitutive and stress-induced HSP90 isoforms and their
RT   conformationally restricted mutants.";
RL   PLoS ONE 10:E0141786-E0141786(2015).
RN   [43]
RP   INTERACTION WITH LECT2.
RX   PubMed=27334921; DOI=10.1074/jbc.m116.720375;
RA   Zheng H., Miyakawa T., Sawano Y., Asano A., Okumura A., Yamagoe S.,
RA   Tanokura M.;
RT   "Crystal structure of human leukocyte cell-derived chemotaxin 2 (LECT2)
RT   reveals a mechanistic basis of functional evolution in a mammalian protein
RT   with an M23 metalloendopeptidase fold.";
RL   J. Biol. Chem. 291:17133-17142(2016).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1356-1359 IN COMPLEX WITH GRB2.
RX   PubMed=11063574; DOI=10.1021/bi0012336;
RA   Schiering N., Casale E., Caccia P., Giordano P., Battistini C.;
RT   "Dimer formation through domain swapping in the crystal structure of the
RT   Grb2-SH2-Ac-pYVNV complex.";
RL   Biochemistry 39:13376-13382(2000).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1049-1360 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=14559966; DOI=10.1073/pnas.1734128100;
RA   Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R.,
RA   Rusconi L., Cristiani C.;
RT   "Crystal structure of the tyrosine kinase domain of the hepatocyte growth
RT   factor receptor c-Met and its complex with the microbial alkaloid K-252a.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12654-12659(2003).
RN   [46]
RP   STRUCTURE BY NMR OF 519-562, AND DISULFIDE BONDS.
RX   PubMed=15358240; DOI=10.1016/j.bbrc.2004.06.132;
RA   Kozlov G., Perreault A., Schrag J.D., Park M., Cygler M., Gehring K.,
RA   Ekiel I.;
RT   "Insights into function of PSI domains from structure of the Met receptor
RT   PSI domain.";
RL   Biochem. Biophys. Res. Commun. 321:234-240(2004).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (3.22 ANGSTROMS) OF 25-567 IN COMPLEX WITH HGF, AND
RP   DISULFIDE BONDS.
RX   PubMed=15167892; DOI=10.1038/sj.emboj.7600243;
RA   Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C.;
RT   "Crystal structure of the HGF beta-chain in complex with the Sema domain of
RT   the Met receptor.";
RL   EMBO J. 23:2325-2335(2004).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-740 IN COMPLEX WITH
RP   L.MONOCYTOGENES INLB, FUNCTION (MICROBIAL INFECTION), INTERACTION WITH
RP   L.MONOCYTOGENES INLB (MICROBIAL INFECTION), AND DISULFIDE BONDS.
RX   PubMed=17662939; DOI=10.1016/j.cell.2007.05.037;
RA   Niemann H.H., Jager V., Butler P.J., van den Heuvel J., Schmidt S.,
RA   Ferraris D., Gherardi E., Heinz D.W.;
RT   "Structure of the human receptor tyrosine kinase Met in complex with the
RT   Listeria invasion protein InlB.";
RL   Cell 130:235-246(2007).
RN   [49]
RP   VARIANTS RCCP THR-1131; LEU-1188; VAL-1195; ILE-1220; HIS-1228; ASN-1228;
RP   CYS-1230; HIS-1230 AND THR-1250, AND VARIANT VAL-320.
RX   PubMed=9140397; DOI=10.1038/ng0597-68;
RA   Schmidt L., Duh F.-M., Chen F., Kishida T., Glenn G., Choyke P.,
RA   Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R.,
RA   Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A.,
RA   Bernues M., Richard S., Lips C.J.M., Walther M.M., Tsui L.-C., Geil L.,
RA   Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J.,
RA   Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M.,
RA   Zbar B.;
RT   "Germline and somatic mutations in the tyrosine kinase domain of the MET
RT   proto-oncogene in papillary renal carcinomas.";
RL   Nat. Genet. 16:68-73(1997).
RN   [50]
RP   VARIANT RCCP ARG-1094, AND CHARACTERIZATION OF VARIANT RCCP ARG-1094.
RX   PubMed=9563489;
RA   Schmidt L., Junker K., Weirich G., Glenn G., Choyke P., Lubensky I.,
RA   Zhuang Z., Jeffers M., Vande Woude G., Neumann H., Walther M.,
RA   Linehan W.M., Zbar B.;
RT   "Two North American families with hereditary papillary renal carcinoma and
RT   identical novel mutations in the MET proto-oncogene.";
RL   Cancer Res. 58:1719-1722(1998).
RN   [51]
RP   VARIANTS RCCP ILE-1092; ARG-1094; ASP-1106; THR-1131; LEU-1188; ASP-1230;
RP   CYS-1230 AND THR-1250.
RX   PubMed=10433944; DOI=10.1016/s0002-9440(10)65147-4;
RA   Lubensky I.A., Schmidt L., Zhuang Z., Weirich G., Pack S., Zambrano N.,
RA   Walther M.M., Choyke P., Linehan W.M., Zbar B.;
RT   "Hereditary and sporadic papillary renal carcinomas with c-met mutations
RT   share a distinct morphological phenotype.";
RL   Am. J. Pathol. 155:517-526(1999).
RN   [52]
RP   VARIANTS HCC ILE-1173; ARG-1244 AND ILE-1250.
RX   PubMed=9927037;
RA   Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J.,
RA   Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S.,
RA   Zhuang Z., Schmidt L., Zbar B., Lee J.Y.;
RT   "Somatic mutations in the kinase domain of the Met/hepatocyte growth factor
RT   receptor gene in childhood hepatocellular carcinomas.";
RL   Cancer Res. 59:307-310(1999).
RN   [53]
RP   VARIANT RCCP ILE-1092, AND CHARACTERIZATION OF VARIANT RCCP ILE-1092.
RX   PubMed=10417759;
RX   DOI=10.1002/(sici)1097-0215(19990827)82:5<640::aid-ijc4>3.0.co;2-6;
RA   Olivero M., Valente G., Bardelli A., Longati P., Ferrero N., Cracco C.,
RA   Terrone C., Rocca-Rossetti S., Comoglio P.M., Di Renzo M.F.;
RT   "Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase
RT   in a HPRCC family.";
RL   Int. J. Cancer 82:640-643(1999).
RN   [54]
RP   VARIANTS RCCP ILE-1092; LEU-1094; TYR-1094; ASP-1106 AND ASP-1230, AND
RP   CHARACTERIZATION OF VARIANTS RCCP ILE-1092; LEU-1094; TYR-1094; ASP-1106
RP   AND ASP-1230.
RX   PubMed=10327054; DOI=10.1038/sj.onc.1202547;
RA   Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M.,
RA   Lubensky I., Neumann H.P.H., Brauch H., Decker J., Vocke C., Brown J.A.,
RA   Jenkins R., Richard S., Bergerheim U., Gerrard B., Dean M., Linehan W.M.,
RA   Zbar B.;
RT   "Novel mutations of the MET proto-oncogene in papillary renal carcinomas.";
RL   Oncogene 18:2343-2350(1999).
RN   [55]
RP   VARIANT GASTRIC CANCER SER-991, VARIANT ILE-992, CHARACTERIZATION OF
RP   VARIANT GASTRIC CANCER SER-991, AND CHARACTERIZATION OF VARIANT ILE-992.
RX   PubMed=11042681; DOI=10.1038/sj.onc.1203874;
RA   Lee J.-H., Han S.-U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L.,
RA   Zbar B., Vande Woude G.F.V.;
RT   "A novel germ line juxtamembrane Met mutation in human gastric cancer.";
RL   Oncogene 19:4947-4953(2000).
RN   [56]
RP   VARIANT GASTRIC CANCER LEU-773.
RX   PubMed=12920089; DOI=10.1136/jmg.40.8.e97;
RA   Kim I.-J., Park J.-H., Kang H.C., Shin Y., Lim S.-B., Ku J.-L., Yang H.-K.,
RA   Lee K.U., Park J.-G.;
RT   "A novel germline mutation in the MET extracellular domain in a Korean
RT   patient with the diffuse type of familial gastric cancer.";
RL   J. Med. Genet. 40:E97-E97(2003).
RN   [57]
RP   INTERACTION WITH SPSB1; SPSB2; SPSB3 AND SPSB4.
RX   PubMed=15713673; DOI=10.1074/jbc.m413897200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET
RT   and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response
RT   element pathway.";
RL   J. Biol. Chem. 280:16393-16401(2005).
RN   [58]
RP   POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO AUTS9, AND VARIANTS CYS-970 AND
RP   ILE-992.
RX   PubMed=17053076; DOI=10.1073/pnas.0605296103;
RA   Campbell D.B., Sutcliffe J.S., Ebert P.J., Militerni R., Bravaccio C.,
RA   Trillo S., Elia M., Schneider C., Melmed R., Sacco R., Persico A.M.,
RA   Levitt P.;
RT   "A genetic variant that disrupts MET transcription is associated with
RT   autism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:16834-16839(2006).
RN   [59]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-143; LEU-156; ASP-168; SER-375; CYS-970
RP   AND ILE-992.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [60]
RP   VARIANTS TYR-150; ASP-168; TYR-385; ILE-992 AND ILE-1294, CHARACTERIZATION
RP   OF VARIANTS TYR-150; ASP-168; TYR-385; ILE-992 AND ILE-1294, AND POSSIBLE
RP   INVOLVEMENT IN CUP.
RX   PubMed=20949619; DOI=10.1002/humu.21374;
RA   Stella G.M., Benvenuti S., Gramaglia D., Scarpa A., Tomezzoli A.,
RA   Cassoni P., Senetta R., Venesio T., Pozzi E., Bardelli A., Comoglio P.M.;
RT   "MET mutations in cancers of unknown primary origin (CUPs).";
RL   Hum. Mutat. 32:44-50(2011).
RN   [61]
RP   VARIANT LYS-375, AND CHARACTERIZATION OF VARIANT LYS-375.
RX   PubMed=28294470; DOI=10.1111/cas.13233;
RA   Tode N., Kikuchi T., Sakakibara T., Hirano T., Inoue A., Ohkouchi S.,
RA   Tamada T., Okazaki T., Koarai A., Sugiura H., Niihori T., Aoki Y.,
RA   Nakayama K., Matsumoto K., Matsubara Y., Yamamoto M., Watanabe A.,
RA   Nukiwa T., Ichinose M.;
RT   "Exome sequencing deciphers a germline MET mutation in familial epidermal
RT   growth factor receptor-mutant lung cancer.";
RL   Cancer Sci. 108:1263-1270(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the
CC       extracellular matrix into the cytoplasm by binding to hepatocyte growth
CC       factor/HGF ligand. Regulates many physiological processes including
CC       proliferation, scattering, morphogenesis and survival. Ligand binding
CC       at the cell surface induces autophosphorylation of MET on its
CC       intracellular domain that provides docking sites for downstream
CC       signaling molecules. Following activation by ligand, interacts with the
CC       PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1.
CC       Recruitment of these downstream effectors by MET leads to the
CC       activation of several signaling cascades including the RAS-ERK, PI3
CC       kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with
CC       the morphogenetic effects while PI3K/AKT coordinates prosurvival
CC       effects. During embryonic development, MET signaling plays a role in
CC       gastrulation, development and migration of muscles and neuronal
CC       precursors, angiogenesis and kidney formation. In adults, participates
CC       in wound healing as well as organ regeneration and tissue remodeling.
CC       Promotes also differentiation and proliferation of hematopoietic cells.
CC       May regulate cortical bone osteogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:P16056}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for Listeria
CC       monocytogenes internalin InlB, mediating entry of the pathogen into
CC       cells. {ECO:0000269|PubMed:11081636, ECO:0000305|PubMed:17662939,
CC       ECO:0000305|PubMed:19900460}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- ACTIVITY REGULATION: In its inactive state, the C-terminal tail
CC       interacts with the catalytic domain and inhibits the kinase activity.
CC       Upon ligand binding, the C-terminal tail is displaced and becomes
CC       phosphorylated, thus increasing the kinase activity.
CC   -!- SUBUNIT: Heterodimer made of an alpha chain (50 kDa) and a beta chain
CC       (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when
CC       phosphorylated with downstream effectors including STAT3, PIK3R1, SRC,
CC       PCLG1, GRB2 and GAB1. Interacts with SPSB1, SPSB2 and SPSB4 (By
CC       similarity). Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-
CC       1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10,
CC       as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the
CC       presence and in the absence of HGF, however HGF treatment has a
CC       positive effect on this interaction. Interacts with MUC20; prevents
CC       interaction with GRB2 and suppresses hepatocyte growth factor-induced
CC       cell proliferation. Interacts with GRB10. Interacts with PTPN1 and
CC       PTPN2. Interacts with LECT2; this interaction may have an antagonistic
CC       effect on receptor activation (PubMed:27334921). Interacts with
CC       HSP90AA1 and HSP90AB1; the interaction suppresses MET kinase activity
CC       (PubMed:26517842). {ECO:0000250|UniProtKB:P16056,
CC       ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:11063574,
CC       ECO:0000269|PubMed:12147692, ECO:0000269|PubMed:12198496,
CC       ECO:0000269|PubMed:14559966, ECO:0000269|PubMed:14684163,
CC       ECO:0000269|PubMed:15167892, ECO:0000269|PubMed:15314156,
CC       ECO:0000269|PubMed:15713673, ECO:0000269|PubMed:15735664,
CC       ECO:0000269|PubMed:1718989, ECO:0000269|PubMed:17662939,
CC       ECO:0000269|PubMed:18819921, ECO:0000269|PubMed:21784853,
CC       ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:27334921,
CC       ECO:0000269|PubMed:7513258, ECO:0000269|PubMed:9440692}.
CC   -!- SUBUNIT: (Microbial infection) Interacts via extracytoplasmic residues
CC       25-656 with L.monocytogenes InlB; MET can bind HGF, its endogenous
CC       ligand, and InlB simultaneously (PubMed:11081636, PubMed:17662939).
CC       InlB probably dimerizes upon binding to MET, which encourages
CC       subsequent dimerization of MET (Probable).
CC       {ECO:0000269|PubMed:11081636, ECO:0000269|PubMed:17662939,
CC       ECO:0000305|PubMed:19900460}.
CC   -!- INTERACTION:
CC       P08581; P22681: CBL; NbExp=15; IntAct=EBI-1039152, EBI-518228;
CC       P08581; Q96EY1: DNAJA3; NbExp=4; IntAct=EBI-1039152, EBI-356767;
CC       P08581; Q96EY1-2: DNAJA3; NbExp=2; IntAct=EBI-1039152, EBI-3952284;
CC       P08581; P00533: EGFR; NbExp=8; IntAct=EBI-1039152, EBI-297353;
CC       P08581; P09769: FGR; NbExp=2; IntAct=EBI-1039152, EBI-1383732;
CC       P08581; P14210: HGF; NbExp=7; IntAct=EBI-1039152, EBI-1039104;
CC       P08581; P14210-6: HGF; NbExp=3; IntAct=EBI-1039152, EBI-6280319;
CC       P08581; O15357: INPPL1; NbExp=2; IntAct=EBI-1039152, EBI-1384248;
CC       P08581; P35968: KDR; NbExp=3; IntAct=EBI-1039152, EBI-1005487;
CC       P08581; P06239: LCK; NbExp=3; IntAct=EBI-1039152, EBI-1348;
CC       P08581; P07948: LYN; NbExp=2; IntAct=EBI-1039152, EBI-79452;
CC       P08581; P08581: MET; NbExp=2; IntAct=EBI-1039152, EBI-1039152;
CC       P08581; P41218: MNDA; NbExp=3; IntAct=EBI-1039152, EBI-2829677;
CC       P08581; P15941: MUC1; NbExp=2; IntAct=EBI-1039152, EBI-2804728;
CC       P08581; P16333: NCK1; NbExp=2; IntAct=EBI-1039152, EBI-389883;
CC       P08581; O43639: NCK2; NbExp=2; IntAct=EBI-1039152, EBI-713635;
CC       P08581; Q16288: NTRK3; NbExp=2; IntAct=EBI-1039152, EBI-3936704;
CC       P08581; P27986: PIK3R1; NbExp=6; IntAct=EBI-1039152, EBI-79464;
CC       P08581; O00459: PIK3R2; NbExp=11; IntAct=EBI-1039152, EBI-346930;
CC       P08581; Q92569: PIK3R3; NbExp=11; IntAct=EBI-1039152, EBI-79893;
CC       P08581; P19174: PLCG1; NbExp=10; IntAct=EBI-1039152, EBI-79387;
CC       P08581; O43157: PLXNB1; NbExp=7; IntAct=EBI-1039152, EBI-1111488;
CC       P08581; O15031: PLXNB2; NbExp=2; IntAct=EBI-1039152, EBI-722004;
CC       P08581; Q9ULL4: PLXNB3; NbExp=2; IntAct=EBI-1039152, EBI-311073;
CC       P08581; P18031: PTPN1; NbExp=3; IntAct=EBI-1039152, EBI-968788;
CC       P08581; Q06124: PTPN11; NbExp=13; IntAct=EBI-1039152, EBI-297779;
CC       P08581; P23467: PTPRB; NbExp=2; IntAct=EBI-1039152, EBI-1265766;
CC       P08581; Q12913: PTPRJ; NbExp=5; IntAct=EBI-1039152, EBI-2264500;
CC       P08581; Q16827: PTPRO; NbExp=2; IntAct=EBI-1039152, EBI-723739;
CC       P08581; P20936: RASA1; NbExp=15; IntAct=EBI-1039152, EBI-1026476;
CC       P08581; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-1039152, EBI-7879749;
CC       P08581; O60880: SH2D1A; NbExp=3; IntAct=EBI-1039152, EBI-6983382;
CC       P08581; O14796: SH2D1B; NbExp=6; IntAct=EBI-1039152, EBI-3923013;
CC       P08581; Q9NP31: SH2D2A; NbExp=7; IntAct=EBI-1039152, EBI-490630;
CC       P08581; Q8N5H7: SH2D3C; NbExp=4; IntAct=EBI-1039152, EBI-745980;
CC       P08581; Q15464: SHB; NbExp=4; IntAct=EBI-1039152, EBI-4402156;
CC       P08581; P29353: SHC1; NbExp=5; IntAct=EBI-1039152, EBI-78835;
CC       P08581; P98077: SHC2; NbExp=2; IntAct=EBI-1039152, EBI-7256023;
CC       P08581; Q6S5L8: SHC4; NbExp=3; IntAct=EBI-1039152, EBI-9453524;
CC       P08581; Q96IW2: SHD; NbExp=2; IntAct=EBI-1039152, EBI-4402781;
CC       P08581; Q9H6Q3: SLA2; NbExp=4; IntAct=EBI-1039152, EBI-1222854;
CC       P08581; O75159: SOCS5; NbExp=2; IntAct=EBI-1039152, EBI-970130;
CC       P08581; O14544: SOCS6; NbExp=4; IntAct=EBI-1039152, EBI-3929549;
CC       P08581; P12931: SRC; NbExp=4; IntAct=EBI-1039152, EBI-621482;
CC       P08581; Q9ULZ2: STAP1; NbExp=3; IntAct=EBI-1039152, EBI-6083058;
CC       P08581; P43405: SYK; NbExp=3; IntAct=EBI-1039152, EBI-78302;
CC       P08581; P42680: TEC; NbExp=2; IntAct=EBI-1039152, EBI-1383480;
CC       P08581; Q9HBL0: TNS1; NbExp=2; IntAct=EBI-1039152, EBI-3389814;
CC       P08581; Q63HR2: TNS2; NbExp=2; IntAct=EBI-1039152, EBI-949753;
CC       P08581; Q68CZ2: TNS3; NbExp=3; IntAct=EBI-1039152, EBI-1220488;
CC       P08581; Q9UKW4: VAV3; NbExp=2; IntAct=EBI-1039152, EBI-297568;
CC       P08581; P07947: YES1; NbExp=3; IntAct=EBI-1039152, EBI-515331;
CC       P08581; P43403: ZAP70; NbExp=2; IntAct=EBI-1039152, EBI-1211276;
CC       P08581; Q08048: Hgf; Xeno; NbExp=3; IntAct=EBI-1039152, EBI-15655650;
CC       P08581; P0DQD2: inlB; Xeno; NbExp=4; IntAct=EBI-1039152, EBI-1379295;
CC       P08581; P35918: Kdr; Xeno; NbExp=3; IntAct=EBI-1039152, EBI-1555005;
CC       P08581; Q00944: PTK2; Xeno; NbExp=5; IntAct=EBI-1039152, EBI-2896409;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional soluble isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P08581-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08581-2; Sequence=VSP_005005;
CC       Name=3; Synonyms=Soluble MET variant 4;
CC         IsoId=P08581-3; Sequence=VSP_042447, VSP_042448;
CC   -!- TISSUE SPECIFICITY: Expressed in normal hepatocytes as well as in
CC       epithelial cells lining the stomach, the small and the large intestine.
CC       Found also in basal keratinocytes of esophagus and skin. High levels
CC       are found in liver, gastrointestinal tract, thyroid and kidney. Also
CC       present in the brain. Expressed in metaphyseal bone (at protein level)
CC       (PubMed:26637977). {ECO:0000269|PubMed:1719465,
CC       ECO:0000269|PubMed:1917129, ECO:0000269|PubMed:26637977}.
CC   -!- DOMAIN: The kinase domain is involved in SPSB1 binding.
CC   -!- DOMAIN: The beta-propeller Sema domain mediates binding to HGF.
CC   -!- PTM: Autophosphorylated in response to ligand binding on Tyr-1234 and
CC       Tyr-1235 in the kinase domain leading to further phosphorylation of
CC       Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site.
CC       Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Dephosphorylated by
CC       PTPN1 and PTPN2. {ECO:0000269|PubMed:12475979,
CC       ECO:0000269|PubMed:15735664, ECO:0000269|PubMed:1655790,
CC       ECO:0000269|PubMed:18819921, ECO:0000269|PubMed:7513258}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis,
CC       resulting in decreasing plasma membrane receptor abundance, and in
CC       endosomal degradation and/or recycling of internalized receptors.
CC       {ECO:0000269|PubMed:12244174, ECO:0000305|PubMed:26637977}.
CC   -!- PTM: (Microbial infection) Tyrosine phosphorylation is stimulated by
CC       L.monocytogenes InlB. Tyrosine phosphorylation is maximal 10-20 minutes
CC       after treatment with InlB and disappears by 60 minutes. The
CC       phosphorylated residues were not identified.
CC       {ECO:0000269|PubMed:11081636}.
CC   -!- DISEASE: Note=Activation of MET after rearrangement with the TPR gene
CC       produces an oncogenic protein.
CC   -!- DISEASE: Note=Defects in MET may be associated with gastric cancer.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk factors
CC       for HCC are chronic hepatitis B virus (HBV) infection, chronic
CC       hepatitis C virus (HCV) infection, prolonged dietary aflatoxin
CC       exposure, alcoholic cirrhosis, and cirrhosis due to other causes.
CC       {ECO:0000269|PubMed:9927037}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Renal cell carcinoma papillary (RCCP) [MIM:605074]: A subtype
CC       of renal cell carcinoma tending to show a tubulo-papillary architecture
CC       formed by numerous, irregular, finger-like projections of connective
CC       tissue. Renal cell carcinoma is a heterogeneous group of sporadic or
CC       hereditary carcinoma derived from cells of the proximal renal tubular
CC       epithelium. {ECO:0000269|PubMed:10327054, ECO:0000269|PubMed:10417759,
CC       ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397,
CC       ECO:0000269|PubMed:9563489}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A common allele in the promoter region of the MET shows
CC       genetic association with susceptibility to autism in some families.
CC       Functional assays indicate a decrease in MET promoter activity and
CC       altered binding of specific transcription factor complexes.
CC   -!- DISEASE: Note=MET activating mutations may be involved in the
CC       development of a highly malignant, metastatic syndrome known as cancer
CC       of unknown primary origin (CUP) or primary occult malignancy. Systemic
CC       neoplastic spread is generally a late event in cancer progression.
CC       However, in some instances, distant dissemination arises at a very
CC       early stage, so that metastases reach clinical relevance before primary
CC       lesions. Sometimes, the primary lesions cannot be identified in spite
CC       of the progresses in the diagnosis of malignancies.
CC   -!- DISEASE: Deafness, autosomal recessive, 97 (DFNB97) [MIM:616705]: A
CC       form of non-syndromic sensorineural hearing loss with prelingual onset.
CC       Sensorineural deafness results from damage to the neural receptors of
CC       the inner ear, the nerve pathways to the brain, or the area of the
CC       brain that receives sound information. {ECO:0000269|PubMed:25941349}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Osteofibrous dysplasia (OSFD) [MIM:607278]: A congenital
CC       disorder of osteogenesis characterized by non-neoplastic, radiolucent
CC       lesions that affect the cortical bone immediately under the periosteum.
CC       It usually manifests as a painless swelling or anterior bowing of the
CC       long bones, most commonly the tibia and fibula.
CC       {ECO:0000269|PubMed:26637977}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC       Disease-associated variants identified in 4 families cause the deletion
CC       of exon 14. This results in the exclusion of an ubiquitination target
CC       site within the cytoplasmic domain, hence in protein stabilization. The
CC       persistent presence of MET at the cell surface in conditions of ligand-
CC       dependent activation retards osteoblastic differentiation.
CC       {ECO:0000269|PubMed:26637977}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/METID131.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=C-MET entry;
CC       URL="https://en.wikipedia.org/wiki/C-MET";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J02958; AAA59591.1; -; mRNA.
DR   EMBL; X54559; CAB56793.1; -; mRNA.
DR   EMBL; EU826570; ACF47606.1; -; mRNA.
DR   EMBL; AC002080; AAB54047.1; -; Genomic_DNA.
DR   EMBL; AC002543; AAC60383.1; -; Genomic_DNA.
DR   EMBL; AC004416; AAF66137.2; -; Genomic_DNA.
DR   EMBL; CH236947; EAL24359.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83509.1; -; Genomic_DNA.
DR   EMBL; BC130420; AAI30421.1; -; mRNA.
DR   EMBL; U08818; AAB60323.1; ALT_SEQ; mRNA.
DR   EMBL; M35074; AAA59590.1; -; mRNA.
DR   CCDS; CCDS43636.1; -. [P08581-1]
DR   CCDS; CCDS47689.1; -. [P08581-2]
DR   PIR; A40175; TVHUME.
DR   RefSeq; NP_000236.2; NM_000245.3. [P08581-1]
DR   RefSeq; NP_001120972.1; NM_001127500.2. [P08581-2]
DR   PDB; 1FYR; X-ray; 2.40 A; I/J/K/L=1356-1359.
DR   PDB; 1R0P; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1R1W; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1SHY; X-ray; 3.22 A; B=25-567.
DR   PDB; 1SSL; NMR; -; A=519-562.
DR   PDB; 2G15; X-ray; 2.15 A; A=1038-1346.
DR   PDB; 2RFN; X-ray; 2.50 A; A/B=1048-1351.
DR   PDB; 2RFS; X-ray; 2.20 A; A=1048-1351.
DR   PDB; 2UZX; X-ray; 2.80 A; B/D=25-740.
DR   PDB; 2UZY; X-ray; 4.00 A; B/D=25-740.
DR   PDB; 2WD1; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 2WGJ; X-ray; 2.00 A; A=1051-1348.
DR   PDB; 2WKM; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3A4P; X-ray; 2.54 A; A=1049-1360.
DR   PDB; 3BUX; X-ray; 1.35 A; A/C=997-1009.
DR   PDB; 3C1X; X-ray; 2.17 A; A=1049-1360.
DR   PDB; 3CCN; X-ray; 1.90 A; A=1048-1350.
DR   PDB; 3CD8; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 3CE3; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3CTH; X-ray; 2.30 A; A=1049-1360.
DR   PDB; 3CTJ; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3DKC; X-ray; 1.52 A; A=1049-1360.
DR   PDB; 3DKF; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 3DKG; X-ray; 1.91 A; A=1049-1360.
DR   PDB; 3EFJ; X-ray; 2.60 A; A/B=1048-1351.
DR   PDB; 3EFK; X-ray; 2.20 A; A/B=1048-1351.
DR   PDB; 3F66; X-ray; 1.40 A; A/B=1052-1349.
DR   PDB; 3F82; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3I5N; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 3L8V; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3LQ8; X-ray; 2.02 A; A=1051-1348.
DR   PDB; 3Q6U; X-ray; 1.60 A; A=1048-1348.
DR   PDB; 3Q6W; X-ray; 1.75 A; A=1048-1348.
DR   PDB; 3QTI; X-ray; 2.00 A; A/B=1050-1360.
DR   PDB; 3R7O; X-ray; 2.30 A; A=1048-1348.
DR   PDB; 3RHK; X-ray; 1.94 A; A/B=1038-1346.
DR   PDB; 3U6H; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 3U6I; X-ray; 2.10 A; A=1048-1351.
DR   PDB; 3VW8; X-ray; 2.10 A; A=1024-1352.
DR   PDB; 3ZBX; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3ZC5; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3ZCL; X-ray; 1.40 A; A=1051-1348.
DR   PDB; 3ZXZ; X-ray; 1.80 A; A=1051-1348.
DR   PDB; 3ZZE; X-ray; 1.87 A; A=1051-1348.
DR   PDB; 4AOI; X-ray; 1.90 A; A=1051-1348.
DR   PDB; 4AP7; X-ray; 1.80 A; A=1051-1348.
DR   PDB; 4DEG; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 4DEH; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 4DEI; X-ray; 2.05 A; A=1048-1351.
DR   PDB; 4EEV; X-ray; 1.80 A; A=1038-1346.
DR   PDB; 4GG5; X-ray; 2.42 A; A=1038-1346.
DR   PDB; 4GG7; X-ray; 2.27 A; A=1038-1346.
DR   PDB; 4IWD; X-ray; 1.99 A; A=1048-1348.
DR   PDB; 4K3J; X-ray; 2.80 A; B=39-564.
DR   PDB; 4KNB; X-ray; 2.40 A; A/B/C/D=1060-1346.
DR   PDB; 4MXC; X-ray; 1.63 A; A=1038-1346.
DR   PDB; 4O3T; X-ray; 2.99 A; B=25-567.
DR   PDB; 4O3U; X-ray; 3.04 A; B=25-567.
DR   PDB; 4R1V; X-ray; 1.20 A; A=1055-1345.
DR   PDB; 4R1Y; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 4XMO; X-ray; 1.75 A; A=1048-1350.
DR   PDB; 4XYF; X-ray; 1.85 A; A=1048-1351.
DR   PDB; 5DG5; X-ray; 2.60 A; A/B=1038-1346.
DR   PDB; 5EOB; X-ray; 1.75 A; A=1038-1346.
DR   PDB; 5EYC; X-ray; 1.80 A; A=1048-1351.
DR   PDB; 5EYD; X-ray; 1.85 A; A=1048-1351.
DR   PDB; 5HLW; X-ray; 1.97 A; A=1057-1355.
DR   PDB; 5HNI; X-ray; 1.71 A; X/Y=1049-1360.
DR   PDB; 5HO6; X-ray; 1.97 A; A=1049-1360.
DR   PDB; 5HOA; X-ray; 2.14 A; A=1049-1360.
DR   PDB; 5HOR; X-ray; 2.20 A; A=1049-1360.
DR   PDB; 5HTI; X-ray; 1.66 A; A=1038-1346.
DR   PDB; 5LSP; X-ray; 2.60 A; A/P=519-743, X/Y=25-35.
DR   PDB; 5T3Q; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 5UAB; X-ray; 1.90 A; A=1023-1360.
DR   PDB; 5UAD; X-ray; 2.25 A; A=1023-1360.
DR   PDB; 5YA5; X-ray; 1.89 A; A=1038-1346.
DR   PDB; 6GCU; X-ray; 6.00 A; A/D=25-741.
DR   PDB; 6I04; X-ray; 3.10 A; A/B=25-564.
DR   PDB; 6SD9; X-ray; 2.35 A; A=1038-1346.
DR   PDB; 6SDC; X-ray; 1.67 A; A=1038-1346.
DR   PDB; 6SDD; X-ray; 1.93 A; A=1038-1346.
DR   PDB; 6SDE; X-ray; 2.49 A; A=1038-1346.
DR   PDB; 6UBW; X-ray; 2.00 A; A=1023-1360.
DR   PDB; 6WVZ; X-ray; 3.10 A; M=39-564.
DR   PDB; 7B3Q; X-ray; 1.75 A; A=1049-1346.
DR   PDB; 7B3T; X-ray; 2.23 A; A=1049-1346.
DR   PDB; 7B3V; X-ray; 1.93 A; A=1049-1346.
DR   PDB; 7B3W; X-ray; 2.02 A; A=1049-1346.
DR   PDB; 7B3Z; X-ray; 1.80 A; A=1049-1346.
DR   PDB; 7B40; X-ray; 1.76 A; A=1049-1346.
DR   PDB; 7B41; X-ray; 1.97 A; A=1049-1346.
DR   PDB; 7B42; X-ray; 1.80 A; A=1049-1346.
DR   PDB; 7B43; X-ray; 1.87 A; A/B=1049-1346.
DR   PDB; 7B44; X-ray; 1.76 A; A=1049-1346.
DR   PDB; 7MO7; EM; 4.80 A; B/E=1-1390.
DR   PDB; 7MO8; EM; 4.50 A; B=1-1390.
DR   PDB; 7MO9; EM; 4.00 A; E=1-1390.
DR   PDB; 7MOA; EM; 4.90 A; E=1-1390.
DR   PDB; 7MOB; EM; 5.00 A; C/D=1-1390.
DR   PDBsum; 1FYR; -.
DR   PDBsum; 1R0P; -.
DR   PDBsum; 1R1W; -.
DR   PDBsum; 1SHY; -.
DR   PDBsum; 1SSL; -.
DR   PDBsum; 2G15; -.
DR   PDBsum; 2RFN; -.
DR   PDBsum; 2RFS; -.
DR   PDBsum; 2UZX; -.
DR   PDBsum; 2UZY; -.
DR   PDBsum; 2WD1; -.
DR   PDBsum; 2WGJ; -.
DR   PDBsum; 2WKM; -.
DR   PDBsum; 3A4P; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3C1X; -.
DR   PDBsum; 3CCN; -.
DR   PDBsum; 3CD8; -.
DR   PDBsum; 3CE3; -.
DR   PDBsum; 3CTH; -.
DR   PDBsum; 3CTJ; -.
DR   PDBsum; 3DKC; -.
DR   PDBsum; 3DKF; -.
DR   PDBsum; 3DKG; -.
DR   PDBsum; 3EFJ; -.
DR   PDBsum; 3EFK; -.
DR   PDBsum; 3F66; -.
DR   PDBsum; 3F82; -.
DR   PDBsum; 3I5N; -.
DR   PDBsum; 3L8V; -.
DR   PDBsum; 3LQ8; -.
DR   PDBsum; 3Q6U; -.
DR   PDBsum; 3Q6W; -.
DR   PDBsum; 3QTI; -.
DR   PDBsum; 3R7O; -.
DR   PDBsum; 3RHK; -.
DR   PDBsum; 3U6H; -.
DR   PDBsum; 3U6I; -.
DR   PDBsum; 3VW8; -.
DR   PDBsum; 3ZBX; -.
DR   PDBsum; 3ZC5; -.
DR   PDBsum; 3ZCL; -.
DR   PDBsum; 3ZXZ; -.
DR   PDBsum; 3ZZE; -.
DR   PDBsum; 4AOI; -.
DR   PDBsum; 4AP7; -.
DR   PDBsum; 4DEG; -.
DR   PDBsum; 4DEH; -.
DR   PDBsum; 4DEI; -.
DR   PDBsum; 4EEV; -.
DR   PDBsum; 4GG5; -.
DR   PDBsum; 4GG7; -.
DR   PDBsum; 4IWD; -.
DR   PDBsum; 4K3J; -.
DR   PDBsum; 4KNB; -.
DR   PDBsum; 4MXC; -.
DR   PDBsum; 4O3T; -.
DR   PDBsum; 4O3U; -.
DR   PDBsum; 4R1V; -.
DR   PDBsum; 4R1Y; -.
DR   PDBsum; 4XMO; -.
DR   PDBsum; 4XYF; -.
DR   PDBsum; 5DG5; -.
DR   PDBsum; 5EOB; -.
DR   PDBsum; 5EYC; -.
DR   PDBsum; 5EYD; -.
DR   PDBsum; 5HLW; -.
DR   PDBsum; 5HNI; -.
DR   PDBsum; 5HO6; -.
DR   PDBsum; 5HOA; -.
DR   PDBsum; 5HOR; -.
DR   PDBsum; 5HTI; -.
DR   PDBsum; 5LSP; -.
DR   PDBsum; 5T3Q; -.
DR   PDBsum; 5UAB; -.
DR   PDBsum; 5UAD; -.
DR   PDBsum; 5YA5; -.
DR   PDBsum; 6GCU; -.
DR   PDBsum; 6I04; -.
DR   PDBsum; 6SD9; -.
DR   PDBsum; 6SDC; -.
DR   PDBsum; 6SDD; -.
DR   PDBsum; 6SDE; -.
DR   PDBsum; 6UBW; -.
DR   PDBsum; 6WVZ; -.
DR   PDBsum; 7B3Q; -.
DR   PDBsum; 7B3T; -.
DR   PDBsum; 7B3V; -.
DR   PDBsum; 7B3W; -.
DR   PDBsum; 7B3Z; -.
DR   PDBsum; 7B40; -.
DR   PDBsum; 7B41; -.
DR   PDBsum; 7B42; -.
DR   PDBsum; 7B43; -.
DR   PDBsum; 7B44; -.
DR   PDBsum; 7MO7; -.
DR   PDBsum; 7MO8; -.
DR   PDBsum; 7MO9; -.
DR   PDBsum; 7MOA; -.
DR   PDBsum; 7MOB; -.
DR   AlphaFoldDB; P08581; -.
DR   SASBDB; P08581; -.
DR   SMR; P08581; -.
DR   BioGRID; 110391; 200.
DR   CORUM; P08581; -.
DR   DIP; DIP-6023N; -.
DR   ELM; P08581; -.
DR   IntAct; P08581; 164.
DR   MINT; P08581; -.
DR   STRING; 9606.ENSP00000317272; -.
DR   BindingDB; P08581; -.
DR   ChEMBL; CHEMBL3717; -.
DR   DrugBank; DB06896; 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide.
DR   DrugBank; DB08791; 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE.
DR   DrugBank; DB06997; 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide.
DR   DrugBank; DB07969; 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol.
DR   DrugBank; DB08079; AMG-208.
DR   DrugBank; DB16695; Amivantamab.
DR   DrugBank; DB12742; Amuvatinib.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB11791; Capmatinib.
DR   DrugBank; DB08865; Crizotinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB02152; K-252a.
DR   DrugBank; DB07369; N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide.
DR   DrugBank; DB06995; N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide.
DR   DrugBank; DB06314; SGX-523.
DR   DrugBank; DB15133; Tepotinib.
DR   DrugBank; DB12200; Tivantinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugCentral; P08581; -.
DR   GuidetoPHARMACOLOGY; 1815; -.
DR   GlyConnect; 680; 17 N-Linked glycans (6 sites).
DR   GlyGen; P08581; 15 sites, 6 Asn glycans (3 sites), 17 N-linked glycans (6 sites).
DR   iPTMnet; P08581; -.
DR   PhosphoSitePlus; P08581; -.
DR   SwissPalm; P08581; -.
DR   BioMuta; MET; -.
DR   DMDM; 251757497; -.
DR   OGP; P08581; -.
DR   CPTAC; CPTAC-1496; -.
DR   CPTAC; CPTAC-2784; -.
DR   EPD; P08581; -.
DR   jPOST; P08581; -.
DR   MassIVE; P08581; -.
DR   MaxQB; P08581; -.
DR   PaxDb; P08581; -.
DR   PeptideAtlas; P08581; -.
DR   PRIDE; P08581; -.
DR   ProteomicsDB; 52128; -. [P08581-1]
DR   ProteomicsDB; 52129; -. [P08581-2]
DR   ProteomicsDB; 52130; -. [P08581-3]
DR   ABCD; P08581; 52 sequenced antibodies.
DR   Antibodypedia; 3939; 3233 antibodies from 49 providers.
DR   CPTC; P08581; 1 antibody.
DR   DNASU; 4233; -.
DR   Ensembl; ENST00000318493.11; ENSP00000317272.6; ENSG00000105976.16. [P08581-2]
DR   Ensembl; ENST00000397752.8; ENSP00000380860.3; ENSG00000105976.16. [P08581-1]
DR   Ensembl; ENST00000436117.2; ENSP00000410980.2; ENSG00000105976.16. [P08581-3]
DR   GeneID; 4233; -.
DR   KEGG; hsa:4233; -.
DR   MANE-Select; ENST00000397752.8; ENSP00000380860.3; NM_000245.4; NP_000236.2.
DR   UCSC; uc003vij.4; human. [P08581-1]
DR   CTD; 4233; -.
DR   DisGeNET; 4233; -.
DR   GeneCards; MET; -.
DR   HGNC; HGNC:7029; MET.
DR   HPA; ENSG00000105976; Tissue enhanced (liver).
DR   MalaCards; MET; -.
DR   MIM; 114550; phenotype.
DR   MIM; 164860; gene.
DR   MIM; 605074; phenotype.
DR   MIM; 607278; phenotype.
DR   MIM; 616705; phenotype.
DR   neXtProt; NX_P08581; -.
DR   OpenTargets; ENSG00000105976; -.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   Orphanet; 47044; Hereditary papillary renal cell carcinoma.
DR   Orphanet; 106; NON RARE IN EUROPE: Autism.
DR   Orphanet; 488265; Osteofibrous dysplasia.
DR   Orphanet; 319298; Papillary renal cell carcinoma.
DR   Orphanet; 33402; Pediatric hepatocellular carcinoma.
DR   Orphanet; 357191; Selection of therapeutic option in non-small cell lung carcinoma.
DR   PharmGKB; PA30763; -.
DR   VEuPathDB; HostDB:ENSG00000105976; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG3610; Eukaryota.
DR   GeneTree; ENSGT00940000158022; -.
DR   HOGENOM; CLU_005158_0_0_1; -.
DR   InParanoid; P08581; -.
DR   OMA; DEEPGQC; -.
DR   OrthoDB; 408584at2759; -.
DR   PhylomeDB; P08581; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P08581; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-416550; Sema4D mediated inhibition of cell attachment and migration.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6806942; MET Receptor Activation.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8851805; MET activates RAS signaling.
DR   Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling.
DR   Reactome; R-HSA-8865999; MET activates PTPN11.
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   Reactome; R-HSA-8875360; InlB-mediated entry of Listeria monocytogenes into host cell.
DR   Reactome; R-HSA-8875513; MET interacts with TNS proteins.
DR   Reactome; R-HSA-8875555; MET activates RAP1 and RAC1.
DR   Reactome; R-HSA-8875656; MET receptor recycling.
DR   Reactome; R-HSA-8875791; MET activates STAT3.
DR   Reactome; R-HSA-9022699; MECP2 regulates neuronal receptors and channels.
DR   Reactome; R-HSA-9734091; Drug-mediated inhibition of MET activation.
DR   SignaLink; P08581; -.
DR   SIGNOR; P08581; -.
DR   BioGRID-ORCS; 4233; 32 hits in 1116 CRISPR screens.
DR   ChiTaRS; MET; human.
DR   EvolutionaryTrace; P08581; -.
DR   GeneWiki; C-Met; -.
DR   GenomeRNAi; 4233; -.
DR   Pharos; P08581; Tclin.
DR   PRO; PR:P08581; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P08581; protein.
DR   Bgee; ENSG00000105976; Expressed in pigmented layer of retina and 192 other tissues.
DR   ExpressionAtlas; P08581; baseline and differential.
DR   Genevisible; P08581; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005008; F:hepatocyte growth factor receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0017154; F:semaphorin receptor activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0001886; P:endothelial cell morphogenesis; IDA:UniProtKB.
DR   GO; GO:0061436; P:establishment of skin barrier; IMP:CAFA.
DR   GO; GO:0001889; P:liver development; IBA:GO_Central.
DR   GO; GO:0010507; P:negative regulation of autophagy; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1905098; P:negative regulation of guanyl-nucleotide exchange factor activity; IDA:CAFA.
DR   GO; GO:1901299; P:negative regulation of hydrogen peroxide-mediated programmed cell death; IMP:BHF-UCL.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IDA:CAFA.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; IDA:CAFA.
DR   GO; GO:0070495; P:negative regulation of thrombin-activated receptor signaling pathway; IDA:CAFA.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0031016; P:pancreas development; IBA:GO_Central.
DR   GO; GO:0006909; P:phagocytosis; IBA:GO_Central.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:UniProtKB.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:CAFA.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   DisProt; DP02738; -.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR031148; Plexin.
DR   InterPro; IPR002165; Plexin_repeat.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016201; PSI.
DR   InterPro; IPR001627; Semap_dom.
DR   InterPro; IPR036352; Semap_dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016244; Tyr_kinase_HGF/MSP_rcpt.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   PANTHER; PTHR22625; PTHR22625; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF01437; PSI; 1.
DR   Pfam; PF01403; Sema; 1.
DR   Pfam; PF01833; TIG; 3.
DR   PIRSF; PIRSF000617; TyrPK_HGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00429; IPT; 4.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00630; Sema; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF101912; SSF101912; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF81296; SSF81296; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS51004; SEMA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Chromosomal rearrangement;
KW   Deafness; Disease variant; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Non-syndromic deafness; Nucleotide-binding; Phosphoprotein; Proto-oncogene;
KW   Receptor; Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..1390
FT                   /note="Hepatocyte growth factor receptor"
FT                   /id="PRO_0000024440"
FT   TOPO_DOM        25..932
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        933..955
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        956..1390
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          27..515
FT                   /note="Sema"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00352"
FT   DOMAIN          563..655
FT                   /note="IPT/TIG 1"
FT   DOMAIN          657..739
FT                   /note="IPT/TIG 2"
FT   DOMAIN          742..836
FT                   /note="IPT/TIG 3"
FT   DOMAIN          1078..1345
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1212..1390
FT                   /note="Interaction with RANBP9"
FT   REGION          1320..1359
FT                   /note="Interaction with MUC20"
FT                   /evidence="ECO:0000269|PubMed:15314156"
FT   ACT_SITE        1204
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         1084..1092
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         1110
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   SITE            307..308
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000255"
FT   SITE            1003
FT                   /note="Required for ligand-induced CBL-mediated
FT                   ubiquitination"
FT                   /evidence="ECO:0000269|PubMed:12244174"
FT   SITE            1009..1010
FT                   /note="Breakpoint for translocation to form TPR-MET
FT                   oncogene"
FT   MOD_RES         966
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         977
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         990
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         997
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1000
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1003
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         1230
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:12475979"
FT   MOD_RES         1234
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12475979"
FT   MOD_RES         1235
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12475979,
FT                   ECO:0000269|PubMed:1655790"
FT   MOD_RES         1289
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         1349
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12475979,
FT                   ECO:0000269|PubMed:7513258"
FT   MOD_RES         1356
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15735664,
FT                   ECO:0000269|PubMed:7513258"
FT   MOD_RES         1365
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:12475979"
FT   CARBOHYD        45
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        106
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19196183"
FT   CARBOHYD        149
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        202
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        399
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        405
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        607
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        635
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        785
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        879
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        930
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        95..101
FT   DISULFID        98..160
FT   DISULFID        133..141
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        172..175
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        298..363
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        385..397
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZY"
FT   DISULFID        520..538
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        526..561
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        529..545
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        541..551
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        610..624
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZX, ECO:0007744|PDB:2UZY"
FT   DISULFID        697..709
FT                   /evidence="ECO:0000269|PubMed:17662939,
FT                   ECO:0007744|PDB:2UZY"
FT   VAR_SEQ         755..764
FT                   /note="SGGSTITGVG -> RHVNIALIQR (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_042447"
FT   VAR_SEQ         755
FT                   /note="S -> STWWKEPLNIVSFLFCFAS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2819873"
FT                   /id="VSP_005005"
FT   VAR_SEQ         765..1390
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_042448"
FT   VARIANT         143
FT                   /note="R -> Q (in dbSNP:rs35469582)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041738"
FT   VARIANT         150
FT                   /note="H -> Y (found in a case of cancer of unknown primary
FT                   origin; the mutated receptor is still functional and can
FT                   sustain the transformed phenotype; somatic mutation;
FT                   dbSNP:rs1436957498)"
FT                   /evidence="ECO:0000269|PubMed:20949619"
FT                   /id="VAR_064855"
FT   VARIANT         156
FT                   /note="S -> L (in dbSNP:rs56311081)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041739"
FT   VARIANT         168
FT                   /note="E -> D (found in a case of cancer of unknown primary
FT                   origin; the mutated receptor is still functional and can
FT                   sustain the transformed phenotype; somatic mutation;
FT                   dbSNP:rs55985569)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:20949619"
FT                   /id="VAR_041740"
FT   VARIANT         238
FT                   /note="L -> S (in dbSNP:rs34349517)"
FT                   /id="VAR_032478"
FT   VARIANT         316
FT                   /note="I -> M (in dbSNP:rs35225896)"
FT                   /id="VAR_032479"
FT   VARIANT         320
FT                   /note="A -> V (in dbSNP:rs35776110)"
FT                   /evidence="ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006285"
FT   VARIANT         375
FT                   /note="N -> K (found in lung cancer also including cases
FT                   carrying EGFR mutations; unknown pathological significance;
FT                   decreased hepatocyte growth factor-activated receptor
FT                   activity; decreased interaction with HGF;
FT                   dbSNP:rs776693512)"
FT                   /evidence="ECO:0000269|PubMed:28294470"
FT                   /id="VAR_079370"
FT   VARIANT         375
FT                   /note="N -> S (in dbSNP:rs33917957)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032480"
FT   VARIANT         385
FT                   /note="C -> Y (found in a case of cancer of unknown primary
FT                   origin; the mutated receptor is still functional and can
FT                   sustain the transformed phenotype; somatic mutation;
FT                   dbSNP:rs752055485)"
FT                   /evidence="ECO:0000269|PubMed:20949619"
FT                   /id="VAR_064856"
FT   VARIANT         773
FT                   /note="P -> L (in gastric cancer; dbSNP:rs771333219)"
FT                   /evidence="ECO:0000269|PubMed:12920089"
FT                   /id="VAR_032481"
FT   VARIANT         841
FT                   /note="F -> V (in DFNB97; dbSNP:rs794728016)"
FT                   /evidence="ECO:0000269|PubMed:25941349"
FT                   /id="VAR_075757"
FT   VARIANT         964..1010
FT                   /note="Missing (in OSFD; loss of CBL-mediated
FT                   destabilization)"
FT                   /evidence="ECO:0000269|PubMed:26637977"
FT                   /id="VAR_076584"
FT   VARIANT         970
FT                   /note="R -> C (in dbSNP:rs34589476)"
FT                   /evidence="ECO:0000269|PubMed:17053076,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_032482"
FT   VARIANT         991
FT                   /note="P -> S (in gastric cancer; prolonged tyrosine
FT                   phosphorylation in response to HGF/SF; transforming
FT                   activity in athymic nude mice; dbSNP:rs768678989)"
FT                   /evidence="ECO:0000269|PubMed:11042681"
FT                   /id="VAR_032483"
FT   VARIANT         992
FT                   /note="T -> I (found in a case of cancer of unknown primary
FT                   origin; the mutated receptor is still functional and can
FT                   sustain the transformed phenotype; somatic mutation;
FT                   dbSNP:rs56391007)"
FT                   /evidence="ECO:0000269|PubMed:11042681,
FT                   ECO:0000269|PubMed:17053076, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:20949619"
FT                   /id="VAR_032484"
FT   VARIANT         1003
FT                   /note="Y -> S (probable disease-associated variant found in
FT                   lesional sample from a patient with sporadically occurring,
FT                   unilateral osteofibrous dysplasia; somatic mutation;
FT                   complete loss of ligand-induced CBL-mediated
FT                   ubiquitination, resulting in protein stabilization)"
FT                   /evidence="ECO:0000269|PubMed:12244174"
FT                   /id="VAR_076585"
FT   VARIANT         1092
FT                   /note="V -> I (in RCCP; constitutive autophosphorylation;
FT                   dbSNP:rs786202724)"
FT                   /evidence="ECO:0000269|PubMed:10327054,
FT                   ECO:0000269|PubMed:10417759, ECO:0000269|PubMed:10433944"
FT                   /id="VAR_032485"
FT   VARIANT         1094
FT                   /note="H -> L (in RCCP; constitutive autophosphorylation;
FT                   causes malignant transformation in cell lines)"
FT                   /evidence="ECO:0000269|PubMed:10327054"
FT                   /id="VAR_032486"
FT   VARIANT         1094
FT                   /note="H -> R (in RCCP; causes malignant transformation in
FT                   cell lines; dbSNP:rs121913243)"
FT                   /evidence="ECO:0000269|PubMed:10433944,
FT                   ECO:0000269|PubMed:9563489"
FT                   /id="VAR_032487"
FT   VARIANT         1094
FT                   /note="H -> Y (in RCCP; constitutive autophosphorylation;
FT                   causes malignant transformation in cell lines;
FT                   dbSNP:rs121913244)"
FT                   /evidence="ECO:0000269|PubMed:10327054"
FT                   /id="VAR_032488"
FT   VARIANT         1106
FT                   /note="H -> D (in RCCP; constitutive autophosphorylation;
FT                   causes malignant transformation in cell lines)"
FT                   /evidence="ECO:0000269|PubMed:10327054,
FT                   ECO:0000269|PubMed:10433944"
FT                   /id="VAR_032489"
FT   VARIANT         1131
FT                   /note="M -> T (in RCCP; germline mutation;
FT                   dbSNP:rs121913668)"
FT                   /evidence="ECO:0000269|PubMed:10433944,
FT                   ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006286"
FT   VARIANT         1173
FT                   /note="T -> I (in HCC; dbSNP:rs121913675)"
FT                   /evidence="ECO:0000269|PubMed:9927037"
FT                   /id="VAR_032490"
FT   VARIANT         1188
FT                   /note="V -> L (in RCCP; germline mutation;
FT                   dbSNP:rs121913669)"
FT                   /evidence="ECO:0000269|PubMed:10433944,
FT                   ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006287"
FT   VARIANT         1195
FT                   /note="L -> V (in RCCP; somatic mutation;
FT                   dbSNP:rs121913673)"
FT                   /evidence="ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006288"
FT   VARIANT         1220
FT                   /note="V -> I (in RCCP; germline mutation;
FT                   dbSNP:rs121913670)"
FT                   /evidence="ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006289"
FT   VARIANT         1228
FT                   /note="D -> H (in RCCP; somatic mutation;
FT                   dbSNP:rs121913671)"
FT                   /evidence="ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006291"
FT   VARIANT         1228
FT                   /note="D -> N (in RCCP; germline mutation;
FT                   dbSNP:rs121913671)"
FT                   /evidence="ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006290"
FT   VARIANT         1230
FT                   /note="Y -> C (in RCCP; germline mutation;
FT                   dbSNP:rs121913246)"
FT                   /evidence="ECO:0000269|PubMed:10433944,
FT                   ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006292"
FT   VARIANT         1230
FT                   /note="Y -> D (in RCCP; constitutive autophosphorylation;
FT                   causes malignant transformation in cell lines)"
FT                   /evidence="ECO:0000269|PubMed:10327054,
FT                   ECO:0000269|PubMed:10433944"
FT                   /id="VAR_032491"
FT   VARIANT         1230
FT                   /note="Y -> H (in RCCP; somatic mutation;
FT                   dbSNP:rs121913247)"
FT                   /evidence="ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006293"
FT   VARIANT         1244
FT                   /note="K -> R (in HCC; dbSNP:rs121913677)"
FT                   /evidence="ECO:0000269|PubMed:9927037"
FT                   /id="VAR_032492"
FT   VARIANT         1250
FT                   /note="M -> I (in HCC; dbSNP:rs121913676)"
FT                   /evidence="ECO:0000269|PubMed:9927037"
FT                   /id="VAR_032493"
FT   VARIANT         1250
FT                   /note="M -> T (in RCCP; somatic mutation;
FT                   dbSNP:rs121913245)"
FT                   /evidence="ECO:0000269|PubMed:10433944,
FT                   ECO:0000269|PubMed:9140397"
FT                   /id="VAR_006294"
FT   VARIANT         1294
FT                   /note="V -> I (found in a case of cancer of unknown primary
FT                   origin; the mutated receptor is still functional and can
FT                   sustain the transformed phenotype; somatic mutation;
FT                   dbSNP:rs1263785859)"
FT                   /evidence="ECO:0000269|PubMed:20949619"
FT                   /id="VAR_064857"
FT   MUTAGEN         1234
FT                   /note="Y->F: Complete loss of kinase activity and of
FT                   ligand-induced ubiquitination. Alters interaction with
FT                   PTPN1 and PTPN2. Loss of interaction with PTPN1 and PTPN2;
FT                   when associated with F-1235."
FT                   /evidence="ECO:0000269|PubMed:12244174,
FT                   ECO:0000269|PubMed:18819921"
FT   MUTAGEN         1235
FT                   /note="Y->F: Complete loss of kinase activity. Alters
FT                   interaction with PTPN1 and PTPN2. Loss of interaction with
FT                   PTPN1 and PTPN2; when associated with F-1234."
FT                   /evidence="ECO:0000269|PubMed:12244174,
FT                   ECO:0000269|PubMed:18819921"
FT   MUTAGEN         1313
FT                   /note="Y->F: No effect on ligand-induced CBL-mediated
FT                   ubiquitination; when associated with F-1349, F-1356 and
FT                   F-1365."
FT                   /evidence="ECO:0000269|PubMed:12244174"
FT   MUTAGEN         1349
FT                   /note="Y->F: No effect on ligand-induced CBL-mediated
FT                   ubiquitination; when associated with F-1313, F-1356 and
FT                   F-1365."
FT                   /evidence="ECO:0000269|PubMed:12244174"
FT   MUTAGEN         1356
FT                   /note="Y->F: No effect on ligand-induced CBL-mediated
FT                   ubiquitination; when associated with F-1313, F-1349 and
FT                   F-1365."
FT                   /evidence="ECO:0000269|PubMed:12244174"
FT   MUTAGEN         1365
FT                   /note="Y->F: No effect on ligand-induced CBL-mediated
FT                   ubiquitination; when associated with F-1313, F-1349 and
FT                   F-1356."
FT                   /evidence="ECO:0000269|PubMed:12244174"
FT   CONFLICT        237
FT                   /note="V -> A (in Ref. 3; ACF47606)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="K -> R (in Ref. 3; ACF47606)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        720
FT                   /note="F -> S (in Ref. 3; ACF47606)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1191
FT                   /note="G -> A (in Ref. 1; AAA59591)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1272
FT                   /note="L -> V (in Ref. 1; AAA59591, 2; CAB56793 and 6;
FT                   AAA59590)"
FT                   /evidence="ECO:0000305"
FT   HELIX           25..30
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          45..47
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          52..58
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          61..66
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          69..74
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   TURN            75..77
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          80..84
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          93..95
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          97..99
FT                   /evidence="ECO:0007829|PDB:1SHY"
FT   HELIX           103..105
FT                   /evidence="ECO:0007829|PDB:4O3T"
FT   STRAND          111..113
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          119..123
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          125..133
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          135..139
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          141..145
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          155..160
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          166..168
FT                   /evidence="ECO:0007829|PDB:6WVZ"
FT   STRAND          173..175
FT                   /evidence="ECO:0007829|PDB:6I04"
FT   STRAND          182..189
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          192..199
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           205..208
FT                   /evidence="ECO:0007829|PDB:6WVZ"
FT   STRAND          213..219
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           231..233
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           239..241
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   TURN            242..244
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          247..255
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          258..268
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          272..274
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          277..281
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          284..286
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          292..300
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          312..314
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          316..323
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           327..333
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          341..349
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          356..366
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           367..374
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           380..382
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          383..385
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   HELIX           387..390
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          392..394
FT                   /evidence="ECO:0007829|PDB:1SHY"
FT   TURN            395..397
FT                   /evidence="ECO:0007829|PDB:4O3T"
FT   STRAND          418..422
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          424..427
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   TURN            429..436
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          439..447
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          450..457
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          462..466
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          469..471
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          476..480
FT                   /evidence="ECO:0007829|PDB:4K3J"
FT   STRAND          490..493
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   TURN            496..498
FT                   /evidence="ECO:0007829|PDB:4O3T"
FT   STRAND          501..506
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          509..514
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   HELIX           520..522
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   HELIX           526..529
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   HELIX           534..536
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          539..541
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          544..546
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   HELIX           548..550
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          552..554
FT                   /evidence="ECO:0007829|PDB:2UZX"
FT   STRAND          557..559
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          564..574
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          580..586
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          589..592
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          595..598
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          602..605
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   HELIX           614..616
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          619..625
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          633..641
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          646..655
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          658..663
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          665..668
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          674..681
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          688..692
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          698..702
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          704..710
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          718..726
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   STRAND          729..739
FT                   /evidence="ECO:0007829|PDB:5LSP"
FT   HELIX           1048..1050
FT                   /evidence="ECO:0007829|PDB:4EEV"
FT   HELIX           1055..1057
FT                   /evidence="ECO:0007829|PDB:3F66"
FT   HELIX           1060..1066
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1067..1069
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1073..1075
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1076..1087
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1090..1098
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1100..1102
FT                   /evidence="ECO:0007829|PDB:4EEV"
FT   STRAND          1104..1111
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1118..1132
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1144..1146
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1149..1151
FT                   /evidence="ECO:0007829|PDB:3F66"
FT   STRAND          1154..1158
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1165..1170
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   TURN            1172..1174
FT                   /evidence="ECO:0007829|PDB:3ZCL"
FT   HELIX           1178..1197
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1207..1209
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1210..1212
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1218..1220
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1224..1226
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   TURN            1227..1230
FT                   /evidence="ECO:0007829|PDB:7B43"
FT   HELIX           1232..1234
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1236..1238
FT                   /evidence="ECO:0007829|PDB:4KNB"
FT   TURN            1239..1241
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1243..1245
FT                   /evidence="ECO:0007829|PDB:4KNB"
FT   HELIX           1247..1249
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1252..1257
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1262..1277
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   STRAND          1283..1287
FT                   /evidence="ECO:0007829|PDB:4EEV"
FT   HELIX           1289..1291
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1292..1297
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1310..1319
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1324..1326
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   HELIX           1330..1342
FT                   /evidence="ECO:0007829|PDB:4R1V"
FT   TURN            1354..1358
FT                   /evidence="ECO:0007829|PDB:1R0P"
SQ   SEQUENCE   1390 AA;  155541 MW;  9CF896D1273905C3 CRC64;
     MKAPAVLAPG ILVLLFTLVQ RSNGECKEAL AKSEMNVNMK YQLPNFTAET PIQNVILHEH
     HIFLGATNYI YVLNEEDLQK VAEYKTGPVL EHPDCFPCQD CSSKANLSGG VWKDNINMAL
     VVDTYYDDQL ISCGSVNRGT CQRHVFPHNH TADIQSEVHC IFSPQIEEPS QCPDCVVSAL
     GAKVLSSVKD RFINFFVGNT INSSYFPDHP LHSISVRRLK ETKDGFMFLT DQSYIDVLPE
     FRDSYPIKYV HAFESNNFIY FLTVQRETLD AQTFHTRIIR FCSINSGLHS YMEMPLECIL
     TEKRKKRSTK KEVFNILQAA YVSKPGAQLA RQIGASLNDD ILFGVFAQSK PDSAEPMDRS
     AMCAFPIKYV NDFFNKIVNK NNVRCLQHFY GPNHEHCFNR TLLRNSSGCE ARRDEYRTEF
     TTALQRVDLF MGQFSEVLLT SISTFIKGDL TIANLGTSEG RFMQVVVSRS GPSTPHVNFL
     LDSHPVSPEV IVEHTLNQNG YTLVITGKKI TKIPLNGLGC RHFQSCSQCL SAPPFVQCGW
     CHDKCVRSEE CLSGTWTQQI CLPAIYKVFP NSAPLEGGTR LTICGWDFGF RRNNKFDLKK
     TRVLLGNESC TLTLSESTMN TLKCTVGPAM NKHFNMSIII SNGHGTTQYS TFSYVDPVIT
     SISPKYGPMA GGTLLTLTGN YLNSGNSRHI SIGGKTCTLK SVSNSILECY TPAQTISTEF
     AVKLKIDLAN RETSIFSYRE DPIVYEIHPT KSFISGGSTI TGVGKNLNSV SVPRMVINVH
     EAGRNFTVAC QHRSNSEIIC CTTPSLQQLN LQLPLKTKAF FMLDGILSKY FDLIYVHNPV
     FKPFEKPVMI SMGNENVLEI KGNDIDPEAV KGEVLKVGNK SCENIHLHSE AVLCTVPNDL
     LKLNSELNIE WKQAISSTVL GKVIVQPDQN FTGLIAGVVS ISTALLLLLG FFLWLKKRKQ
     IKDLGSELVR YDARVHTPHL DRLVSARSVS PTTEMVSNES VDYRATFPED QFPNSSQNGS
     CRQVQYPLTD MSPILTSGDS DISSPLLQNT VHIDLSALNP ELVQAVQHVV IGPSSLIVHF
     NEVIGRGHFG CVYHGTLLDN DGKKIHCAVK SLNRITDIGE VSQFLTEGII MKDFSHPNVL
     SLLGICLRSE GSPLVVLPYM KHGDLRNFIR NETHNPTVKD LIGFGLQVAK GMKYLASKKF
     VHRDLAARNC MLDEKFTVKV ADFGLARDMY DKEYYSVHNK TGAKLPVKWM ALESLQTQKF
     TTKSDVWSFG VLLWELMTRG APPYPDVNTF DITVYLLQGR RLLQPEYCPD PLYEVMLKCW
     HPKAEMRPSF SELVSRISAI FSTFIGEHYV HVNATYVNVK CVAPYPSLLS SEDNADDEVD
     TRPASFWETS
//
